Peter B. Gilbert

Fred Hutchinson Cancer Center

CoVPN 3002 - A Phase III Randomized, Double-Blind, Placebo-Controlled Multicenter Study in Adults to Determine the safety, Efficacy, and Immunogenicity of AZD1222 for Prevention of Covid-19

CoVPN 3004 A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Immunogenicity of a SARS-CoV-2 Spike Protein Nanoparticle Vaccine in Adults

CoVPN 3008 - Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern

HVTN 405/HPTN 1901 Characterizing SARS-CoV-2-specific immunity in convalescent individuals

CoVPN 3001 - A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults.

CoVPN 3005 - Efficacy, Immunogenicity, and Safety of Two SARS-CoV-2 Recombinant Protein Vaccines with Adjuvant in Adults 18 Years of Age and Older

CoVPN Cross-Protocol Analyses

CoVPN 3006 - A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine

CoVPN 5001 - A prospective study of acute immune responses to SARS-CoV-2 infection

CoVPN 3003 - A Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older SDMC

CoVPN 3006: A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine

CoVPN 5001 A prospective study of acute immune responses to SARS-CoV-2 infection SDMC

CoVPN 3001 A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine SDMC

CoVPN Cross-Protocol Analyses

CoVPN 3003 A Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older SDMC